Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence

Trial Profile

Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 According to a Galena Biopharma media release, interim efficacy analysis is scheduled to be performed by the Data Safety Monitoring Board (DSMB) in the first quarter of 2018. Results from the primary endpoint of the trial are expected in the fourth quarter of 2019.
    • 28 Sep 2017 Status changed from recruiting to active, no longer recruiting according to a Galena Biopharma media release.
    • 12 Jul 2017 According to a Galena Biopharma media release, 293 of the 300 patients are enrolled in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top